Deborah Abrams Kaplan

Individual coverage health reimbursement arrangements (ICHRAs) let employees pick their health insurance policy.

Many provisions of the Affordable Care Act are popular and the healthcare reform law has brought the proportion of Americans without healthcare insurance down to an all-time low. As president, Donald Trump backed "repeal and replace" efforts.

Reproductive rights and abortion: The hottest healthcare issue

Incorporating hospice care into Medicare Advantage didn’t work out, and CMS is looking to identify low-quality providers.

Generation Z (1997–2012). Everything on demand, including healthcare

Gen X (1965–1980), still traditional — and stuck in the middle.

Two herring fishing businesses are challenging the so-called Chevron deference that gives federal agencies considerable leeway in setting regulations. The Supreme Court heard their cases in January.

The number of people living to 100 is growing in the U.S. and around the world. Defying the overall trend of older people having more health issues, they are not major users of healthcare.

The track record on outsourcing clinical services is mixed.

Three hot topics to keep an eye on for the remainder of this year and into 2024. This is the second part of a two-part series.

Three hot topics to keep an eye on for the remainder of this year and into 2024. This is the first part of a two-part series.

Experts say the successes and failures of alternative payment models (APMs) over the past decade have taught us a few things.

Alternative payment models are still coming into focus, but so far, they haven’t lived up to the high expectations.

Anesthesiologists and emergency department physicians have formed organizations to push back against the firms.

Less government oversight, a sense of urgency and the rise of telehealth created new openings for healthcare scam artists. Providers need to have their guard up.

For-profit companies now dominate hospice care in the U.S., and private equity firms are moving in. Some say the trend reflects the underlying economics and need for scale.

Commercial plans haven’t traditionally covered hearing aids.

This part of the month's cover story series features private equity and how it's coming for primary care. Jane Zhu, M.D., M.P.P., of Oregon Health & Science University shares that private equity takes advantage of economies of scale to make things more streamlined, then move onto the next market or specialty. This months cover story shines a light on the companies, trends and ideas that are shaking things up and reshaping the contour of how healthcare is paid for and delivered.

Repositories of donated drugs in 13 states are redistributing oncology medications to those in need.

Andrew Shadid and Genesis Orthopedics & Sports Medicine applied some of the principles of reverse innovation to make the practice successful.

More practices are directly dispensing oral cancer drugs, bypassing specialty pharmacies. What does this trend mean for patients and healthcare?

Insulin, albuterol, epinephrine, glucagon and naloxone are on the list.

Drug manufacturers are rejecting the program’s blanket discounts involving contract pharmacies. A flurry of litigation has ensued.

The Big Three all set up group purchasing organizations recently, but some industry observers question the timing of the move and who will benefit.

A Kaiser Family Foundation survey found that all the responding programs had at least one initiative to expand behavioral health services.

The company is expanding the reach of Amazon Care and partnering with health systems and senior living companies to support at-home care.

The agency has been in the spotlight because of the pandemic, questions about its independence and the approval of Aduhelm. The stakes are high and the politics, fraught.

Copays and formulary tiers involve financial incentives to use certain drugs. But is Cigna’s offer of a $500 debit card in a different category?

Government regulations are designed to encourage data fluidity in healthcare, which could "radically empower" consumers, said Kim Diehl-Boyd, CoverMyMeds vice president of industry relations and government affairs, at the 2021 Annual National Conference of the Pharmacy Benefit Management Institute.

FDA approval of Lumakras was contingent on a trial testing lower doses. It could usher in a new era of optimal dosing instead of the maximum tolerated dosing.